Do analysts prefer RLYB or KZIA?

Novogen has a consensus target price of $25.80, indicating a potential upside of 110.44%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Rallybio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67

Which has preferable valuation and earnings, RLYB or KZIA?

Rallybio has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rallybio $860K 100.52 -$8.98M -$4.34 N/A Novogen $30K 674.30 -$13.41M N/A N/A

Is RLYB or KZIA more profitable?

Novogen has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Novogen's return on equity of 0.00% beat Rallybio's return on equity. Company Net Margins Return on Equity Return on Assets Rallybio -911.07% -55.79% -51.48% Novogen N/A N/A N/A

Which has preferable earnings and valuation, RANI or KZIA?

Novogen has lower revenue, but higher earnings than Rani Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Rani Therapeutics $1.63M 64.67 -$29.67M -$0.41 N/A Novogen $30K 674.30 -$13.41M N/A N/A

Is RANI or KZIA more profitable?

Novogen's return on equity of 0.00% beat Rani Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Rani Therapeutics N/A -206.46% -83.95% Novogen N/A N/A N/A

Which has higher earnings & valuation, CGTX or KZIA?

Novogen has higher revenue and earnings than Cognition Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cognition Therapeutics N/A N/A -$23.49M -$0.24 N/A Novogen $30K 674.30 -$13.41M N/A N/A

Is CGTX or KZIA more profitable?

Novogen's return on equity of 0.00% beat Cognition Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cognition Therapeutics N/A -72.68% -53.07% Novogen N/A N/A N/A

Do analysts recommend KZIA or SPRO?

Novogen currently has a consensus target price of $25.80, indicating a potential upside of 110.44%. Given Novogen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novogen is more favorable than Spero Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation & earnings, KZIA or SPRO?

Spero Therapeutics has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 674.30 -$13.41M N/A N/A Spero Therapeutics $66.80M 1.03 $8.57M $0.24 4.96

Which has better earnings and valuation, FRMM or KZIA?

Novogen has lower revenue, but higher earnings than Forum Markets. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Forum Markets $6.55M 11.71 -$450.52M -$36.07 N/A Novogen $30K 674.30 -$13.41M N/A N/A

Is FRMM or KZIA more profitable?

Novogen's return on equity of 0.00% beat Forum Markets' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Novogen N/A N/A N/A

Novogen (KZIA) Competitors

$12.26 -0.78 (-5.98%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$12.28 +0.02 (+0.16%)

As of 07/24/2026 07:34 PM Eastern

Compare

KZIA vs. RLYB, RANI, CGTX, SPRO, and FRMM

Should you buy Novogen stock or one of its competitors? MarketBeat compares Novogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novogen include Rallybio (RLYB), Rani Therapeutics (RANI), Cognition Therapeutics (CGTX), Spero Therapeutics (SPRO), and Forum Markets (FRMM). These companies are all part of the "pharmaceutical products" industry.

How does Novogen compare to Rallybio?

Rallybio (NASDAQ:RLYB) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Rallybio has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$860K	100.52	-$8.98M	-$4.34	N/A
Novogen	$30K	674.30	-$13.41M	N/A	N/A

Rallybio has a beta of -0.9, meaning that its stock price is 190% less volatile than the broader market. Comparatively, Novogen has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

90.3% of Rallybio shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 10.3% of Rallybio shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Rallybio had 1 more articles in the media than Novogen. MarketBeat recorded 2 mentions for Rallybio and 1 mentions for Novogen. Novogen's average media sentiment score of 1.89 beat Rallybio's score of 1.44 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Rallybio	Positive
Novogen	Very Positive

Novogen has a net margin of 0.00% compared to Rallybio's net margin of -911.07%. Novogen's return on equity of 0.00% beat Rallybio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rallybio	-911.07%	-55.79%	-51.48%
Novogen	N/A	N/A	N/A

Novogen has a consensus target price of $25.80, indicating a potential upside of 110.44%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Rallybio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Novogen beats Rallybio on 9 of the 14 factors compared between the two stocks.

How does Novogen compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, media sentiment, profitability, risk and earnings.

In the previous week, Rani Therapeutics had 1 more articles in the media than Novogen. MarketBeat recorded 2 mentions for Rani Therapeutics and 1 mentions for Novogen. Novogen's average media sentiment score of 1.89 beat Rani Therapeutics' score of 0.93 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Rani Therapeutics	Positive
Novogen	Very Positive

Rani Therapeutics presently has a consensus target price of $8.75, indicating a potential upside of 928.32%. Novogen has a consensus target price of $25.80, indicating a potential upside of 110.44%. Given Rani Therapeutics' higher possible upside, equities analysts clearly believe Rani Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by company insiders. Comparatively, 1.0% of Novogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Rani Therapeutics has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market. Comparatively, Novogen has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market.

Novogen's return on equity of 0.00% beat Rani Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-206.46%	-83.95%
Novogen	N/A	N/A	N/A

Novogen has lower revenue, but higher earnings than Rani Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	64.67	-$29.67M	-$0.41	N/A
Novogen	$30K	674.30	-$13.41M	N/A	N/A

Summary

Novogen beats Rani Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Novogen compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 30.9% of Novogen shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by insiders. Comparatively, 1.0% of Novogen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Novogen's return on equity of 0.00% beat Cognition Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Novogen	N/A	N/A	N/A

Novogen has higher revenue and earnings than Cognition Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Novogen	$30K	674.30	-$13.41M	N/A	N/A

In the previous week, Cognition Therapeutics and Cognition Therapeutics both had 1 articles in the media. Novogen's average media sentiment score of 1.89 beat Cognition Therapeutics' score of 1.87 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Cognition Therapeutics	Very Positive
Novogen	Very Positive

Cognition Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Cognition Therapeutics currently has a consensus target price of $3.33, indicating a potential upside of 262.52%. Novogen has a consensus target price of $25.80, indicating a potential upside of 110.44%. Given Cognition Therapeutics' higher possible upside, research analysts plainly believe Cognition Therapeutics is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Novogen beats Cognition Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Novogen compare to Spero Therapeutics?

Novogen (NASDAQ:KZIA) and Spero Therapeutics (NASDAQ:SPRO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, dividends, institutional ownership, profitability and valuation.

Novogen currently has a consensus target price of $25.80, indicating a potential upside of 110.44%. Given Novogen's stronger consensus rating and higher probable upside, equities research analysts clearly believe Novogen is more favorable than Spero Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Spero Therapeutics has a net margin of 24.90% compared to Novogen's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat Novogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
Spero Therapeutics	24.90%	35.58%	24.95%

30.9% of Novogen shares are owned by institutional investors. Comparatively, 25.6% of Spero Therapeutics shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 2.9% of Spero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Spero Therapeutics had 2 more articles in the media than Novogen. MarketBeat recorded 3 mentions for Spero Therapeutics and 1 mentions for Novogen. Novogen's average media sentiment score of 1.89 beat Spero Therapeutics' score of 1.12 indicating that Novogen is being referred to more favorably in the media.

Company	Overall Sentiment
Novogen	Very Positive
Spero Therapeutics	Positive

Spero Therapeutics has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	674.30	-$13.41M	N/A	N/A
Spero Therapeutics	$66.80M	1.03	$8.57M	$0.24	4.96

Novogen has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, Spero Therapeutics has a beta of 1.49, suggesting that its stock price is 49% more volatile than the broader market.

Summary

Novogen and Spero Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Novogen compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and Novogen (NASDAQ:KZIA) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, media sentiment, profitability and institutional ownership.

Forum Markets presently has a consensus target price of $10.00, indicating a potential upside of 74.52%. Novogen has a consensus target price of $25.80, indicating a potential upside of 110.44%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Novogen	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67

Novogen has lower revenue, but higher earnings than Forum Markets.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	11.71	-$450.52M	-$36.07	N/A
Novogen	$30K	674.30	-$13.41M	N/A	N/A

4.1% of Forum Markets shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 25.2% of Forum Markets shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Forum Markets has a beta of 1.37, meaning that its share price is 37% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, meaning that its share price is 114% more volatile than the broader market.

Novogen's return on equity of 0.00% beat Forum Markets' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Novogen	N/A	N/A	N/A

In the previous week, Forum Markets had 1 more articles in the media than Novogen. MarketBeat recorded 2 mentions for Forum Markets and 1 mentions for Novogen. Novogen's average media sentiment score of 1.89 beat Forum Markets' score of 0.94 indicating that Novogen is being referred to more favorably in the news media.

Company	Overall Sentiment
Forum Markets	Positive
Novogen	Very Positive

Summary

Novogen beats Forum Markets on 10 of the 14 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$20.27M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	N/A	21.48	27.14	23.64
Price / Sales	674.30	169.92	517.01	89.03
Price / Cash	N/A	157.90	50.54	59.64
Price / Book	-2.30	7.88	10.28	6.07
Net Income	-$13.41M	$23.86M	$3.60B	$331.99M
7 Day Performance	-8.10%	-3.82%	-1.27%	-0.63%
1 Month Performance	-11.93%	-2.61%	-0.37%	-2.00%
1 Year Performance	24.85%	32.79%	18.30%	13.62%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	2.2148 of 5 stars	$12.26 -6.0%	$25.80 +110.4%	+23.1%	$20.27M	$30K	N/A	12	Positive News
RLYB Rallybio	1.6312 of 5 stars	$16.91 +1.2%	N/A	+289.1%	$88.53M	$860K	N/A	40	Positive News Short Interest Decrease
RANI Rani Therapeutics	1.8862 of 5 stars	$0.69 +0.7%	$8.75 +1,166.3%	+69.7%	$85.02M	$1.63M	N/A	110	Gap Down
CGTX Cognition Therapeutics	2.2921 of 5 stars	$1.00 +5.4%	$3.33 +233.3%	+6.7%	$84.90M	N/A	N/A	20	Positive News
SPRO Spero Therapeutics	1.8094 of 5 stars	$1.38 -4.2%	N/A	-49.4%	$83.38M	$66.80M	5.75	150	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. RLYB, RANI, CGTX, SPRO, and FRMM

How does Novogen compare to Rallybio?

Summary

How does Novogen compare to Rani Therapeutics?

Summary

How does Novogen compare to Cognition Therapeutics?

Summary

How does Novogen compare to Spero Therapeutics?

Summary

How does Novogen compare to Forum Markets?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. RLYB, RANI, CGTX, SPRO, and FRMM

How does Novogen compare to Rallybio?

Which has preferable valuation and earnings, RLYB or KZIA?

Which has more volatility and risk, RLYB or KZIA?

Do institutionals and insiders believe in RLYB or KZIA?

Does the media refer more to RLYB or KZIA?

Is RLYB or KZIA more profitable?

Do analysts prefer RLYB or KZIA?

Summary

How does Novogen compare to Rani Therapeutics?

Does the media favor RANI or KZIA?

Do analysts prefer RANI or KZIA?

Do insiders & institutionals have more ownership in RANI or KZIA?

Which has more risk and volatility, RANI or KZIA?

Is RANI or KZIA more profitable?

Which has preferable earnings and valuation, RANI or KZIA?

Summary

How does Novogen compare to Cognition Therapeutics?

Do insiders and institutionals hold more shares of CGTX or KZIA?

Is CGTX or KZIA more profitable?

Which has higher earnings & valuation, CGTX or KZIA?

Does the media refer more to CGTX or KZIA?

Which has more volatility & risk, CGTX or KZIA?

Do analysts recommend CGTX or KZIA?

Summary

How does Novogen compare to Spero Therapeutics?

Do analysts recommend KZIA or SPRO?

Is KZIA or SPRO more profitable?

Do insiders & institutionals believe in KZIA or SPRO?

Does the media prefer KZIA or SPRO?

Which has higher valuation & earnings, KZIA or SPRO?

Which has more volatility and risk, KZIA or SPRO?

Summary

How does Novogen compare to Forum Markets?

Do analysts recommend FRMM or KZIA?

Which has better earnings and valuation, FRMM or KZIA?

Do institutionals & insiders believe in FRMM or KZIA?

Which has more volatility and risk, FRMM or KZIA?

Is FRMM or KZIA more profitable?

Does the media prefer FRMM or KZIA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools